Akaeso Pharmaceuticals is proud to have assembled a world-class Board of Directors with extensive experience and expertise in the pharmaceutical industry. Comprising seasoned professionals and leaders in their respective fields, our board members bring a wealth of knowledge and strategic vision to guide our company's growth and success.
Our board consists of distinguished individuals with deep industry insight, encompassing drug development, commercialization, regulatory affairs, and corporate partnerships. Their collective expertise allows us to navigate the complex landscape of the pharmaceutical sector, ensuring sound decision-making and effective execution of our business strategies.
Drawing upon their vast experience, our board members play a vital role in shaping Akaeso's vision and providing valuable guidance to our management team. They bring a wealth of industry relationships, strategic perspectives, and a commitment to advancing the development of innovative therapies for patients in need.
With their proven track records and dedication to excellence, our board members exemplify the highest standards of corporate governance and leadership. Their invaluable contributions help position Akaeso Pharmaceuticals as a trusted and forward-thinking organization, driving us towards our mission of transforming the landscape of healthcare through breakthrough drug development and strategic partnerships.
Our Scientific Leadership Team comprises a group of distinguished experts who are at the forefront of scientific innovation and drug development. With their exceptional knowledge and experience, they drive our research and development efforts, shaping the future of medicine.
Our Scientific Leadership Team consists of accomplished scientists, researchers, and medical professionals who bring a diverse range of expertise to our organization. They possess deep understanding and specialization in areas such as rare diseases, fibrosis, and other therapeutic fields, allowing us to tackle the most challenging medical needs.
The Scientific Leadership Team's extensive industry experience, coupled with their unwavering commitment to scientific excellence, enables us to identify and develop novel therapies that have the potential to make a significant impact on patients' lives. Together, we are pushing the boundaries of innovation and working towards a future where unmet medical needs are addressed through groundbreaking treatments.
Akaeso Pharmaceuticals operates on a highly effective and financially prudent business model that positions us as a compelling investment opportunity in the pharmaceutical industry.
Our business model is built upon the strategic integration of drug development expertise, collaboration with research institutions, and a focus on securing corporate partnerships with pharmaceutical companies. By leveraging these key elements, we have created a streamlined and efficient approach to bringing novel drugs to market.
At the core of our business model is our ability to identify promising drug candidates that have already undergone initial discovery and testing. By licensing or acquiring these compounds, we significantly reduce the time and resources required for early-stage research, allowing us to expedite the development process.
our emphasis on collaboration and strategic partnerships enables us to access a global network of research institutions, biotech companies, and academic experts. This collaborative approach minimizes costs and expands our scientific knowledge base, providing us with a competitive advantage in the industry.
Through our business model, we de-risk the drug development process by focusing on compounds with proven potential and advancing them to a stage where they become attractive to larger pharmaceutical companies. This strategy not only optimizes our resources but also positions us for lucrative corporate deals and licensing agreements, ensuring a significant return on investment for our shareholders.
Akaesos’ strategy as a route to market is through corporate deals, either licensing the rights for each product to companies which are in the sector. This could be done on a world-wide level with multinational companies, or at a regional or even national level with local companies, in return of royalties and milestone payments. The Company intends to enter into industry partnerships early, which minimises the need for capital as the high drug development costs are incurred in large clinical trials. The strategy of the company in terms of commercialisation means that it does not need to set up and fund a sales and marketing organisation and can access directly the substantial worldwide selling capabilities and structures of the big pharma companies. This strategy and options are in-line with the Company’s focus on maintaining a low-cost base and avoiding hiring numerous commercial people. Importantly, as a validation for this rationale, the strategy capitalises on the trends in the pharmaceutical industry for licensing new products and acquisitions.
The global pharmaceutical drugs market is estimated at $1.14 trillion in 2022 and is expected to reach $1.64 trillion in 2026 at a CAGR of 9.5%, according to a report by Research And Markets published in September 2022.
Fibrotic diseases represent a significant market opportunity with a growing demand for effective treatments and therapies. Liver fibrosis, kidney fibrosis, idiopathic pulmonary fibrosis (IPF), cystic fibrosis, myocardial fibrosis, and scleroderma are among the key fibrotic diseases affecting millions of people worldwide.
Fibrosis is defined by excess deposition of fibrous connective tissue as the result of various stimuli such as infections, mechanical injury, allergic responses and autoimmune reactions. Repair of injured tissue is a fundamental biological process which allows the replacement of injured cells, but when this process is imbalanced pathogenic and permanent fibrosis can be formed. Fibrotic disorders such as pulmonary and cardiovascular fibrosis have an enormous impact on human health. Nephropathy is very frequent and serious complication of diabetes. Affected patients often require hemodialysis and eventually kidney transplantation to and have an increased risk of cardiovascular disease. Given the impact and complexity of these diseases, novel and effective therapies are urgently needed.
Liver fibrosis, often caused by chronic liver diseases, impacts liver function and can progress to cirrhosis. Kidney fibrosis leads to impaired kidney function and potential organ failure. IPF, a chronic lung disease, results in breathing difficulties and reduced lung function. Cystic fibrosis affects multiple organs, primarily the lungs and digestive system. Myocardial fibrosis involves scar tissue buildup in the heart, impairing cardiac function. Scleroderma causes skin thickening, organ damage, and systemic symptoms due to excessive collagen production.
The prevalence of fibrotic diseases underscores the urgent need for innovative therapies. Akaeso Pharmaceuticals is strategically positioned to address this unmet medical need by developing novel treatments and collaborating with research institutions, biotech companies, and pharmaceutical partners. By investing in Akaeso, you have the opportunity to be part of a promising market with vast potential, making a significant impact on patients' lives and capturing substantial returns on your investment.
Summary
The Code of Conduct determines the way in which the company works towards achieving its mission and objectives and governs the way everyone conducts themselves.
• Conduct business with honesty, integrity and transparency.
• Strive for professionalism in everything we do.
• Embrace continuous improvements and innovation.
• Treat everyone with dignity and respect.
• No compromise on quality.
• Reliability and consistency in delivering what is promised.
• Result orientation and customer dedication.
The Directors of Akaeso recognise that as a player in the health sector that is prevalent globally, it will strive to act responsibly and at all times to uphold its foundation and business values.
Global Reporting Initiative
Reporting Framework
• Providing useful information Integrated beyond financial statements.
• How companies create value in the short, medium and long-term.
• Through strategy governance.
• Environmental considerations.
• Social considerations.
The aim therefore is for the Directors to provide transparent, forward- looking information by:
• Reporting on the different categories of capital and demonstrating the connectivity between these.
• Showing how tangible and intangible assets create financial and non-financial value, both inside and outside the organization.
• Reporting on Non-financial performance – increasingly becoming very important.
• Always being seen that the company is “Doing the right things right”
• Constantly improving the perception of the company.
• Linking strategy with the day-to-day running of the company.
Corporate Social Responsibility
The Company’s Directors recognize the importance of its role as a member of the global community and as such will always strive to act as a responsible corporate citizen.
The company’s aim is to sell its products across the world and it is imperative that a relationship synonymous with quality, trust and respect is maintained with all its customers and wider stakeholders.
These standards apply to ethical, environmental, cultural and social spheres.
Search investors section
Summary of Articles
The delegation of daily management responsibilities within a company involves assigning individuals, such as an "afgevaardigd bestuurder" or "algemeen directeur", to handle day-to-day operations. The board of directors determines the terms and limits of this delegation.
Appointment of auditors or "commissarissen" to monitor the company's financial situation, annual accounts, and compliance with regulations: The number of auditors and their remuneration are determined by the general assembly. Auditors have access to company records and can delegate certain powers for specific purposes.
The general assembly, comprising shareholders, plays a crucial role in decision-making. Other topics in our articles include process of convening meetings, shareholder admission requirements, proxy representation rights, and the election of assembly officers. Key decisions made by the assembly include the approval of annual accounts, profit distribution, dividend payments, and the dissolution and liquidation of the company.
The articles provide a comprehensive overview of the delegation of management, the role of auditors, and the functioning of the general assembly within our company.
